Dyslipidemias Clinical Trial
Official title:
The Therapeutic Effects of Combination of Statins With Berberine on the Patients With Hyperlipemia:a Single-center, Open Clinical Trial
Statins are cholesterol-lowering medications that are often prescribed for patients with high cholesterol and who are at risk for cardiovascular disease (CVD). But there are many patients whose hyperlipemia are not well controlled. If investigators are simply doubling the statins, that only 6% of the benefit can be received. And it often has significant side effects in elder patients. Several studies have suggested that the use of berberine can effectively lower blood lipids. The chemical structure and mechanisms of drug is clearly, and the side effects are seldom, the price of berberine is very cheap. The purpose of this study is to observe the therapeutic effects of combination of statins and berberine on the patients with hyperlipemia whose level of the lipid are not well controlled when only using statins.
Patients at risk for cardiovascular disease (CVD) are often prescribed statins, which are
medications that reduce the amount of cholesterol in the blood. By lowering cholesterol
levels, these patients have a lower incidence of coronary artery disease, ischemic stroke,
and peripheral arterial disease and so on. But there are many patients whose hyperlipemia
are not well controlled.If investigators are simply doubling the statins, that only 6% of
the benefit can be received.And it often bring significant side effects in elder patients.
Several studies have suggested that the use of berberine can effectively lowering blood
lipids.The chemical structure and mechanisms of drug is clearly, and the side effects are
seldom, the price of berberine is very cheap. The purpose of this study is to observe the
therapeutic effects of combination of statins and berberine on the patients with
hyperlipemia whose level of the lipid are not well controlled when only using statins.
This study will enroll patients who currently take cholesterol-lowering medications,but the
level of lipid is not controlled well. Patients will be assigned to receive 500mg of
Berberine twice a day(meanwhile they are taking 20mg of Atorvastatin daily for 8 weeks or
10mg of Rosuvastatin daily for 8 weeks). Investigators will occur at baseline and Weeks 4
and 8. Blood will be collected for laboratory testing, and standardized psychological
questionnaires will assess fatigue at baseline and weeks 4 and 8. Pill count will be used to
assess adherence of Berberine and statins treatment at weeks 4 and 8. At weeks 4 and 8,
medication side effects will be monitored and tests of alanine aminotransferase (ALT) and
creatine phosphate kinase (CPK) will be performed. At weeks 4 and 8, medication efficacy
will be assessed and test of low-density lipoprotein cholesterol (LDL-C) will be performed.
;
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT04591808 -
Efficacy and Safety of Atorvastatin + Perindopril Fixed-Dose Combination S05167 in Adult Patients With Arterial Hypertension and Dyslipidemia
|
Phase 3 | |
Completed |
NCT04894318 -
The Effect Of Low-Fat And Low-Cholesterol Dietary Intervention On LDL Sub-Groups In Turkısh Dyslipidemic Patients
|
N/A | |
Completed |
NCT04862962 -
Study to Evaluate the Safety of the Fixed-dose Combination Rosuvastatin/Ezetimibe for Patients With Dyslipidaemia
|
||
Completed |
NCT04052594 -
A Study of LY3475766 in Healthy Participants
|
Phase 1 | |
Active, not recruiting |
NCT04270084 -
Metabolic Optimization Through Diet/Lifestyle Improvements For Youth
|
N/A | |
Completed |
NCT03241121 -
Study of Eating Patterns With a Smartphone App and the Effects of Time Restricted Feeding in the Metabolic Syndrome
|
N/A | |
Completed |
NCT04516291 -
A Dose-Ranging Study With Vupanorsen (TRANSLATE-TIMI 70)
|
Phase 2 | |
Completed |
NCT03170752 -
Implementing and Testing a Cardiovascular Assessment Screening Program (CASP)
|
N/A | |
Completed |
NCT05124847 -
TREating Pediatric Obesity
|
N/A | |
Completed |
NCT04186780 -
Effects of Lentinula Edodes Bars on Dyslipidemia and Oxidative Stress in Cholesterol Individuals: Randomized Study
|
N/A | |
Not yet recruiting |
NCT03674333 -
Effect of Adding Folic Acid on Lipid Parameters in Population With Dyslipidemias
|
N/A | |
Not yet recruiting |
NCT06159543 -
The Effects of Fresh Mango Consumption on Cardiometabolic Outcomes in Free-living Individuals With Prediabetes
|
N/A | |
Completed |
NCT00362908 -
Effects of Low and Moderate Fat Diets on Lipids, Inflammation and Vascular Reactivity in the Metabolic Syndrome
|
N/A | |
Completed |
NCT00455325 -
Chloroquine to Treat People With Metabolic Syndrome Aim2 (ARCH-MS)
|
Phase 2 | |
Completed |
NCT00644709 -
A Study Of Atorvastatin For The Treatment Of High Cholesterol In Patients At High Risk Of Coronary Heart Disease (CHD)
|
Phase 4 | |
Recruiting |
NCT05624658 -
Effect of Combined Lipid-lowering Therapy on Atherosclerotic Plaque Vulnerability in Patients With ACS
|
N/A | |
Recruiting |
NCT03988101 -
Role of Statin in Venous Dysfunction in Patients With Venous Thromboembolism Event
|
Phase 4 | |
Recruiting |
NCT06024291 -
Reducing Circulating Sphingolipid Levels to Optimise Cardiometabolic Health - The SphingoFIT Trial
|
N/A | |
Completed |
NCT01218204 -
A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Administering Multiple Oral Doses of GSK1292263 Alone and With Atorvastatin
|
Phase 2 | |
Completed |
NCT04079530 -
A Clinical Pharmacology Study of K-877 Controlled Release Tablet
|
Phase 2 |